Mechanistically, miR-33b directly targets TAK1, thereby decreasing the expression of FASN and CPT1A in ovarian cancer cells, which reduces OCM-promoted fatty acid synthesis and ATP production. Here, CPT1A is linked to ovarian carcinoma.